CAMK2B
MOLECULAR TARGETcalcium/calmodulin dependent protein kinase II beta
CAMK2B (calcium/calmodulin dependent protein kinase II beta) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CAMK2B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | ruxolitinib | 4.23 | 68 |
| 3 | palbociclib | 4.22 | 67 |
| 4 | doramapimod | 4.06 | 57 |
| 5 | bi 2536 | 4.01 | 54 |
| 6 | midostaurin | 3.85 | 46 |
| 7 | abemaciclib | 3.66 | 38 |
| 8 | tae 684 | 3.43 | 30 |
| 9 | fedratinib | 3.40 | 29 |
| 10 | lestaurtinib | 3.04 | 20 |
| 11 | atuveciclib | 2.56 | 12 |
| 12 | gsk 461364 | 2.40 | 10 |
| 13 | su 014813 | 2.20 | 8 |
| 14 | rg 547 | 2.08 | 7 |
| 15 | Quercetin | 0.69 | 1 |
| 16 | KN 92 [Supplementary Concept] KN 93 isomer; | 0.69 | 1 |
| 17 | Sorafenib | 0.69 | 1 |
| 18 | sp600125 | 0.69 | 1 |
About CAMK2B as a Drug Target
CAMK2B (calcium/calmodulin dependent protein kinase II beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented CAMK2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CAMK2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.